Cargando…

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer

BACKGROUND AND PURPOSE: We investigated the incidence and dose-volume relationships of radiation pneumonitis (RP) after concurrent chemoradiotherapy (CCRT) followed by durvalumab for locally advanced non-small-cell lung cancer (LA-NSCLC). MATERIALS AND METHODS: We retrospectively analyzed records of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Satoshi, Abe, Takanori, Kobayashi, Nao, Aoshika, Tomomi, Ryuno, Yasuhiro, Igari, Mitsunobu, Hirai, Ryuta, Kumazaki, Yu, Miura, Yu, Kaira, Kyoichi, Kagamu, Hiroshi, Noda, Shin-ei, Kato, Shingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283100/ https://www.ncbi.nlm.nih.gov/pubmed/32529055 http://dx.doi.org/10.1016/j.ctro.2020.05.006

Ejemplares similares

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy
por: Saito, Satoshi, et al.
Publicado: (2021)

Stereotactic body radiation therapy using CyberKnife for T1N0M0 lung cancer patients with severe pulmonary dysfunction
por: Abe, Takanori, et al.
Publicado: (2020)

Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer
por: Abe, Takanori, et al.
Publicado: (2021)

Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non‐small cell lung cancer treated with intensity modulated radiotherapy
por: Abe, Takanori, et al.
Publicado: (2022)

High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study
por: Ryuno, Yasuhiro, et al.
Publicado: (2022)

Learning curve of lung dose optimization in intensity‐modulated radiotherapy for locally advanced non‐small cell lung cancer
por: Igari, Mitsunobu, et al.
Publicado: (2023)

Results of definitive radiotherapy with concurrent chemotherapy for maxillary sinus carcinomas with neck lymph node metastasis
por: Abe, Takanori, et al.
Publicado: (2020)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Development of an HDR‐BT QA tool for source position verification
por: Kumazaki, Yu, et al.
Publicado: (2020)

Dosimetric comparison of three-dimensional conformal radiotherapy versus volumetric-arc radiotherapy in cervical cancer treatment: applying the central-shielding principle to modern technology
por: Tamaki, Tomoaki, et al.
Publicado: (2018)

Dose–volume parameters and local tumor control in cervical cancer treated with central-shielding external-beam radiotherapy and CT-based image-guided brachytherapy
por: Okazaki, Shohei, et al.
Publicado: (2019)

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
por: Kaira, Kyoichi, et al.
Publicado: (2020)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
por: Oshiro, Yoshiko, et al.
Publicado: (2021)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Durvalumab: Immune-related pneumonitis: case report
Publicado: (2021)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC
por: Jing, Wang, et al.
Publicado: (2022)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cell‐like features
por: Shiono, Ayako, et al.
Publicado: (2020)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report
por: Kobayashi, Kunihiko, et al.
Publicado: (2021)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Spontaneous aspiration of a long tree twig as foreign body
por: Hashimoto, Kosuke, et al.
Publicado: (2019)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
por: Faehling, Martin, et al.
Publicado: (2020)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis
por: Huang, Sherri, et al.
Publicado: (2022)

Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma
por: Mikami, Erika, et al.
Publicado: (2023)

Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
por: Yamaguchi, Ou, et al.
Publicado: (2020)

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
por: Hashimoto, Kosuke, et al.
Publicado: (2020)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t2fdggs07j4bi8i09na1q9tht2